"Four challenges" for Bayer to face before considering break-up

5 March 2024
bayer_big

Announcing its financial results for 2023, diversified German drugmaker (BAYN: DE) said it would delay a plan to break up the group for at least a couple of years.

The firm reported sales of 11.9 billion euros ($12.9 billion) in the last quarter, a rise of 5.5%, and 47.6 billion euros for the full year.

Net income was 1.3 billion euros for the quarter, with a loss of 2.9 billion euros for the year as a whole, leading respectively to earnings per share (EPS) of 1.36 euros and minus three euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical